The study will use two different antibiotics: ceftriaxone, which is given through an intravenous infusion (through a vein), and amoxicillin, which is taken as tablets by mouth. These medications will target specific bacteria that have been found in the fatty deposits that build up in the arteries of patients with heart attacks.

During the study, patients will receive antibiotic treatment for up to two weeks. The medications will be used to target bacteria that are commonly found in complicated artery blockages. Patients will be monitored for heart-related events and complications over several years after receiving the treatment.

The research will examine how well orticumab works compared to placebo in treating coronary artery inflammation. The inflammation will be measured using a special technique called Fat Attenuation Index score, which is determined through Coronary Computed Tomography Angiography (a detailed heart imaging scan). The study will look at three main blood vessels of the heart: the right coronary artery, left anterior descending artery, and left circumflex artery.

Participants in this study will receive treatment for 6 months. During this time, they will undergo various health checks, including blood tests, physical examinations, and heart scans. The study will monitor both the effectiveness of the treatment and any side effects that may occur. Throughout the study, participants will continue taking their regular heart medications as prescribed by their doctors.

The trial will involve several medications, including Warfarin, Lysine Aspirin, Clopidogrel, Acetylsalicylic Acid, Atorvastatin, Diltiazem, Bisoprolol, Acetylcholine Chloride, Glyceryl Trinitrate, and Ramipril. These medications are used for various purposes such as preventing blood clots, reducing cholesterol, and managing heart conditions. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual medications.

Participants in the study will be monitored over a period of 12 months. During this time, their angina status and quality of life will be assessed using a questionnaire. The study will also track any major cardiovascular events, such as heart attacks or strokes, and evaluate the costs associated with healthcare for MINOCA patients. Additionally, the study will investigate the use of certain biomarkers, which are substances in the blood that can help diagnose and understand the causes of MINOCA, as well as the use of Cardiac Magnetic Resonance Imaging (CMR) to evaluate the condition. The goal is to gather information that could lead to better treatment strategies for people with MINOCA.

Participants in the study will receive either the new treatment plan or the standard treatment plan. The study will last for about a year, during which the health of the participants will be monitored to see how well the treatments work. The study will also look at different ways of completing a procedure called revascularization, which helps restore blood flow to the heart. This will be done using either a method called Optical Coherence Tomography (OCT), which uses light waves to take pictures of the heart, or a standard method called angiography, which uses X-rays.

The main goal is to see if the new treatment plan is not worse than the standard plan in terms of preventing serious health problems like heart attacks, strokes, or bleeding. Additionally, the study aims to find out if using OCT for revascularization is better than using angiography in terms of the size of the area where a stent, a small tube used to keep blood vessels open, is placed. Participants will be followed up at different times to check for any major health events and to assess the success of the treatments.

Participants in the study will be randomly assigned to receive either one of the beta-blocker medications or a placebo. The study will last for a period of up to 77 days, during which participants will take the medication daily. Throughout the study, participants will be monitored for any changes in their health, particularly focusing on heart-related events. The study aims to gather information on whether these medications can reduce the risk of serious heart problems and improve overall health outcomes for patients who have had a heart attack.

In addition to the main focus on heart health, the study will also look at other aspects such as the quality of life, any side effects from the medications, and how these medications might affect other conditions like Chronic Obstructive Pulmonary Disease or diabetes. The findings from this study could provide valuable insights into the benefits and risks of using beta-blockers in patients with a history of heart attack but without reduced heart function.

Participants in the study will receive either the ferric carboxymaltose treatment or a placebo. The study will monitor the participants over a period of up to 36 months. During this time, researchers will track various health outcomes, including the number of heart failure events, which are instances where the heart does not pump blood as well as it should, and changes in a specific blood marker called NT-proBNP, which is often elevated in heart failure. Additionally, the study will assess changes in the participants’ quality of life using a questionnaire known as EQ-5D.

The study aims to provide valuable insights into whether treating iron deficiency with ferric carboxymaltose can improve survival rates and reduce heart-related complications in patients who have recently had a heart attack. By understanding these effects, the study hopes to contribute to better management and treatment strategies for individuals with these health conditions.

The purpose of the study is to assess the safety of ApTOLL at two different doses in patients who are candidates for emergency procedures to open blocked heart arteries, known as angioplasty, without having received clot-dissolving medications. Participants in the study will receive ApTOLL through an intravenous bolus, which means it is given directly into a vein in a single, quick dose. The study will monitor participants for any adverse effects, such as severe low blood pressure, irregular heart rhythms, or heart failure, over a period of 90 days after receiving the treatment.

Throughout the study, the effects of ApTOLL on the heart will be measured using imaging techniques like MRI and echocardiography. These tests will help determine changes in the size of the heart attack area and the heart’s ability to pump blood. Additionally, the study will measure levels of certain proteins in the blood that indicate inflammation and heart damage. These measurements will be taken at various times after the treatment to understand how ApTOLL affects the heart and the body’s response to the heart attack.

Participants in the study will receive either aspirin or a placebo, which looks like the aspirin tablet but does not contain any active medication. The study will also involve another medication called pantoprazole, which is used to protect the stomach lining. The treatment period will last for up to 90 days, and the researchers will monitor the participants’ health for any heart-related events and other outcomes over a period of 180 days.

The goal of this study is to determine if aspirin can provide additional benefits in preventing heart-related complications in patients with pneumonia. By understanding the potential benefits of aspirin in this context, the study hopes to improve treatment strategies for patients with pneumonia who are at risk of heart problems. Participants will be closely monitored throughout the study to ensure their safety and well-being.

The purpose of the study is to compare the effects of the flu vaccine with a placebo in reducing inflammation in the heart after a heart attack. Participants in the study will receive either the flu vaccine or a placebo. The study will monitor changes in heart inflammation over a period of eight weeks. This will be done using a special imaging technique called computed tomography (CT), which helps visualize the heart and surrounding tissues.

Throughout the study, various health markers will be measured to assess the impact of the flu vaccine on heart inflammation. These include changes in specific proteins and cells in the blood that are related to inflammation. The study will also look at other indicators of heart health, such as levels of certain proteins that are released when the heart is under stress. The trial is expected to continue until 2027, with recruitment starting in 2024.

The purpose of the study is to see if patients with a heart attack who are at high risk of bleeding can safely switch to a personalized, less intense DAPT strategy. This involves using clopidogrel and a shorter duration of DAPT, guided by a genetic test called Cytochrome P2C19-genotyping. The goal is to reduce bleeding without increasing the risk of further heart problems. Participants in the study will be randomly assigned to different treatment groups, which may include a placebo, and will be monitored over a period of time to assess the safety and effectiveness of the treatment strategies.

The trial will track several outcomes, including the occurrence of any major health events such as death, another heart attack, or stroke, as well as any significant bleeding events. The study aims to provide valuable information that could improve treatment strategies for heart attack patients who are at high risk of bleeding, potentially leading to safer and more effective care options in the future.

Participants in the study will receive either Prasugrel or Ticagrelor, which are medications that help prevent blood clots by stopping platelets (a type of blood cell) from sticking together. These medications will be compared to other treatments, including Acetylsalicylic Acid (commonly known as aspirin) and Clopidogrel, which also work to prevent blood clots but in different ways. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients.

The study will last for several weeks, during which participants will take the assigned medication and be monitored for any heart-related events or bleeding issues. The goal is to determine if the stronger blood-thinning medications can effectively reduce the risk of heart problems without significantly increasing the risk of bleeding. The results of this study could help improve treatment strategies for patients with atrial fibrillation and acute coronary syndrome who undergo PCI.